Charles River Laboratories International Inc
Charles River Laboratories International Inc (CRL) Implied Volatility Current
CRL's 30 day implied volatility is 51.07%, with an IV Rank of 53.97%. This is an average IV Rank versus the past year, meaning Charles River Laboratories International Inc options are fairly priced and currently offer no clear edge to buyers or sellers. CRL's 30 day historical volatility sits at 57.40%, which means implied volatility is running 6.33 points below historical volatility, as of Nov 19, 2026.
Read more
Tracking CRL implied volatility helps you spot when Charles River Laboratories International Inc options are historically cheap or expensive, and where the best trades are hiding. When CRL IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor CRL implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking CRL IV rank helps you see whether CRL's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services.
Implied Volatility
IV is slightly elevated. Premiums are richer, leaning toward sellers.
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →